Wall Street analysts expect Aquestive Therapeutics to report Q2 2026 revenue of $14.22 million and a net loss of $0.11 per share, with the current $4.25 share price sitting well below the $15.00 average analyst target.
Investors are primarily focused on the regulatory timeline for Anaphylm, the company's sublingual epinephrine film candidate, following its recent New Drug Application (NDA) submission.
Management is expected to provide updates on the FDA's acceptance of the filing and potential PDUFA dates which are critical for the stock's valuation. Stable revenue growth from existing products like Sympazan and royalty streams continues to support the company's cash runway during this pivotal clinical-to-commercial transition.